GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00713755 | Liver | NAFLD | cellular response to peptide hormone stimulus | 65/1882 | 290/18723 | 3.95e-10 | 9.62e-08 | 65 |
GO:00082023 | Liver | NAFLD | steroid metabolic process | 69/1882 | 319/18723 | 5.90e-10 | 1.28e-07 | 69 |
GO:00160327 | Liver | NAFLD | viral process | 80/1882 | 415/18723 | 7.71e-09 | 1.07e-06 | 80 |
GO:19016536 | Liver | NAFLD | cellular response to peptide | 71/1882 | 359/18723 | 1.82e-08 | 2.09e-06 | 71 |
GO:00302585 | Liver | NAFLD | lipid modification | 49/1882 | 212/18723 | 1.97e-08 | 2.17e-06 | 49 |
GO:00072654 | Liver | NAFLD | Ras protein signal transduction | 66/1882 | 337/18723 | 8.43e-08 | 7.09e-06 | 66 |
GO:00434346 | Liver | NAFLD | response to peptide hormone | 76/1882 | 414/18723 | 1.51e-07 | 1.09e-05 | 76 |
GO:00160495 | Liver | NAFLD | cell growth | 85/1882 | 482/18723 | 1.75e-07 | 1.25e-05 | 85 |
GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
GO:00192163 | Liver | NAFLD | regulation of lipid metabolic process | 61/1882 | 331/18723 | 2.18e-06 | 9.24e-05 | 61 |
GO:00718252 | Liver | NAFLD | protein-lipid complex subunit organization | 17/1882 | 50/18723 | 3.92e-06 | 1.54e-04 | 17 |
GO:00718272 | Liver | NAFLD | plasma lipoprotein particle organization | 16/1882 | 46/18723 | 5.37e-06 | 1.95e-04 | 16 |
GO:00190587 | Liver | NAFLD | viral life cycle | 57/1882 | 317/18723 | 1.00e-05 | 3.18e-04 | 57 |
GO:00072664 | Liver | NAFLD | Rho protein signal transduction | 31/1882 | 137/18723 | 1.19e-05 | 3.67e-04 | 31 |
GO:00343682 | Liver | NAFLD | protein-lipid complex remodeling | 12/1882 | 30/18723 | 1.58e-05 | 4.56e-04 | 12 |
GO:00343692 | Liver | NAFLD | plasma lipoprotein particle remodeling | 12/1882 | 30/18723 | 1.58e-05 | 4.56e-04 | 12 |
GO:00343672 | Liver | NAFLD | protein-containing complex remodeling | 12/1882 | 32/18723 | 3.40e-05 | 8.80e-04 | 12 |
GO:0015850 | Liver | NAFLD | organic hydroxy compound transport | 50/1882 | 284/18723 | 6.01e-05 | 1.32e-03 | 50 |
GO:00444037 | Liver | NAFLD | biological process involved in symbiotic interaction | 50/1882 | 290/18723 | 1.03e-04 | 2.04e-03 | 50 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AGTR1 | SNV | Missense_Mutation | | c.855N>G | p.Phe285Leu | p.F285L | | protein_coding | tolerated(0.58) | benign(0.401) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
AGTR1 | SNV | Missense_Mutation | rs762020328 | c.482N>A | p.Arg161Gln | p.R161Q | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AGTR1 | SNV | Missense_Mutation | rs200184769 | c.605N>A | p.Arg202Gln | p.R202Q | | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AGTR1 | SNV | Missense_Mutation | rs770227887 | c.485N>G | p.Tyr162Cys | p.Y162C | | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AGTR1 | SNV | Missense_Mutation | novel | c.1021N>T | p.Gly341Trp | p.G341W | | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | SD |
AGTR1 | SNV | Missense_Mutation | novel | c.61N>T | p.Val21Leu | p.V21L | | protein_coding | | unknown(0) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
AGTR1 | insertion | Frame_Shift_Ins | novel | c.253_254insTCATTTACTTTTATATGAAGCTGAAGACAGCT | p.Val87TyrfsTer10 | p.V87Yfs*10 | | protein_coding | | | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
AGTR1 | SNV | Missense_Mutation | | c.143N>T | p.Arg48Ile | p.R48I | | protein_coding | tolerated(0.09) | benign(0.05) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AGTR1 | SNV | Missense_Mutation | novel | c.414N>G | p.Ile138Met | p.I138M | | protein_coding | tolerated(0.11) | benign(0.403) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
AGTR1 | SNV | Missense_Mutation | novel | c.947N>G | p.Asp316Gly | p.D316G | | protein_coding | deleterious(0.04) | probably_damaging(0.992) | TCGA-VS-A957-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | CHEMBL57242 | AZILSARTAN | |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | | LOSARTAN | LOSARTAN | |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | CHEMBL1200692 | OLMESARTAN MEDOXOMIL | |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | | DNDI1417147 | CHEMBL2094484 | |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | | Eprosartan | EPROSARTAN | |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | CHEMBL1069 | VALSARTAN | |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | | Forasartan | FORASARTAN | |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | | nitrendipine | NITRENDIPINE | 8952600 |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | CHEMBL1017 | TELMISARTAN | |
185 | AGTR1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | 178103484 | | |